Editas Medicine, Inc. 于2013年9月以Gengine, Inc.名字成立，后来在2013年11月更名为Editas Medicine, Inc.该公司是一家领先的基因研究公司，致力于通过纠正患者的致病基因治疗与基因相关的疾病。
Editas Medicine Inc is a US-based genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company only operating segment being developing and commercializing genome editing technology.